The program guidelines were: consume 2530 g of fiber per day by eating fruits, vegetables, and whole grains
The Intensifying GLP-1 Race While Novo Nordisk recently secured FDA approval for an oral version of semaglutide becoming the first to market an oral GLP-1RA for obesity Eli Lilly continues to lead in injectable sales with: Zepbound (obesity) Mounjaro (type 2 diabetes) Lilly is also awaiting an FDA decision on its oral candidate, orforglipron
Genazzani AD, Tomatis V, Manzo A, et al
Do not attempt to "compensate" by skipping subsequent doses without medical guidance
Based on the TRIUMPH program structure and Lilly's track record with tirzepatide, the most likely filing sequence is: Obesity Expected to be the first indication filed, with the BLA planned for Q1 2027
We induced APAP hepatotoxicity in mice either sufficient of serotonin (wild-type mice and TPH1-/- plus 5- Hydroxytryptophan (5-HTP)) or lacking peripheral serotonin ( Tph1-/- and wild-type mice plus p-chlorophenylalanine (PCPA)).Mice with sufficient 5-HT exposed to acetaminophen have a significantly lower mortality rate and a better outcome compared with mice deficient of 5-HT
